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Escherichia coli O157:H7hasbeen responsibleformultiplefood-andwaterborneoutbreaks ofdiarrhea and/orhemorrhagiccolitis
(HC) worldwide. More importantly, a portion of E. coli O157:H7-infected individuals, particularly young children, develop a life-
threatening sequela of infection called hemolytic uremic syndrome (HUS). Shiga toxin (Stx), a potent cytotoxin, is the major
virulence factor linked to the presentation of both HC and HUS. Currently, treatment of E. coli O157:H7 and other Stx-producing
E. coli (STEC) infections is limited to supportive care. To facilitate development of therapeutic strategies and vaccines for humans
against these agents, animal models that mimic one or more aspect of STEC infection and disease are needed. In this paper, we
focusonthecharacteristics ofvariousmousemodelsthathavebeendeveloped andthatcanbeused tomonitorSTECcolonization,
disease, pathology, or combinations of these features as well as the impact of Stx alone.
1.Introduction
Escherichia coli O157:H7 is a member of a group of
pathogenic E. coli (known as enterohemorrhaghic E. coli
or EHEC) that colonize the gastrointestinal tract and cause
a condition known as hemorrhagic colitis (HC) or bloody
diarrhea. E. coli O157:H7 is also a member of the larger
categoryofShiga toxin-producing E.coli(STEC).This group
of E. coli is solely deﬁned by its capacity to produce Shiga
toxin type 1 (Stx1), Shiga toxin type 2 (Stx2), or both toxins
(as well as variants of these). The capacityof STECin general
andE.coliO157:H7andotherEHECinparticulartoproduce
Stxs makes them of particular concern because Stx has been
linked to the development of hemolytic uremic syndrome
(HUS)thatcanleadtokidneyfailure,particularly inchildren
[1, 2].
While a number of STEC serotypes are known to
cause disease worldwide, E. coli O157:H7 infection generally
represents the largest of the STEC disease burden, both
in the United States (USA) and worldwide. Although the
ﬁrst recorded outbreak due to organisms of this serotype in
the United Statesoccurred in 1982, E. coli O157:H7infection
in both people and animals can be traced back as early as
the 1970’s. The prevalence of this pathogen has grown since
its ﬁrst description and, despite our best control measures,
E. coli O157:H7 remains a serious health concern (Figure 1)
[1, 3–8].
E. coli O157:H7 is responsible for an estimated 73,480
casesofillness,2,168hospitalizations,and61deathsannually
in USA, according to data published by Mead et al. in 1999
[9]. The majority of such E. coli O157:H7 outbreaks in the
USA are associated with foodborne transmission [4]. Cattle
as well as other ruminants serve as a reservoir for E. coli
O157:H7. In particular, surveys of beef and dairy cattle have
demonstratedcarriagerateslessthan0.5togreaterthan2.0%
[10]. As a result of E. coli O157:H7 carriage in cattle, beef,
and dairy products often become contaminated and serve
as the source of infection in outbreaks of E. coli O157:H7.
Many vehiclesforfoodbornetransmission ofE.coliO157:H7
have been described including beef (ground beef, roast beef,
steak, salami, etc.), produce (unpasteurized apple cider or
juice, melons, grapes, lettuce, bean sprouts, spinach, etc.),2 Journal of Biomedicine and Biotechnology
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Figure 1: Major outbreaks of E. coli O157:H7 infection. Outbreaks are listed by year and in the context of key discoveries that linked Stx
with development of HUS.
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Figure 2: Modes of E. coli O157:H7 transmission to humans with
emphasis on strategies for prevention/intervention. Other modes
of transmission of E. coli O157:H7 have been reported and are
described elsewhere.
and dairy products (raw milk, cheese, butter, etc.) [4]. The
spread of E. coli O157:H7 by these various food matrices
is facilitated not only by the pathogen’s low infectious dose
[11], but additionally by the pathogen’s capacity to grow
over a broad temperature range and to survive both freezing
and acidic conditions [12]. In addition to transmission
from contaminated food (or drink), person-to-person and
waterborne transmission (both likely facilitated by the low
infectious dose of E. coli O157:H7 [11, 13]) have also been
reported (Figure 2).
E. coli O157:H7 infection can manifest in a variety of
ways. Some individuals who are infected with the microbe
remain asymptomatic, others experience diarrhea, but most
develop hemorrhagic colitis, the hallmark of E. coli O157:H7
infection. Furthermore, children and the elderly appear
to be especially susceptible to E. coli O157:H7-mediated
disease and, for reasons that are unclear, may develop
HUS (a triad of clinical manifestations including hemolytic
anemia, thrombocytopenia, and renal failure [14]) and
other systemic problems that include central nervous system
(CNS) impairment.
Arise in both thehospitalization and HUSrates has been
reported in association with more recent outbreaks of E. coli
O157:H7. In data collected from outbreaks that occurred
between 1982 and 2002, the average hospitalization rate was
just over 17% and the average rate of HUS was ∼4% [4].
However, in the spinach outbreak in 2006 and the cookie
dough outbreak in 2009, rates of hospitalization and HUS
were even higher (approximately 51% and 16%, respectively,
in the spinach outbreak and approximately 44% and 13%,
respectively, in the cookie dough outbreak [7, 8]). This
increase in disease severity among E. coli O157:H7 infected
persons has led to speculation that more virulent strains of
the pathogen have emerged [15].Journal of Biomedicine and Biotechnology 3
Although it has been nearly 30 years since the discovery
of E. coli O157:H7 as an enteric pathogen and despite
the recent increase in the rate of severe disease associated
with infection by the organism, no treatment yet exists.
In general, antibiotic therapy is contraindicated as it may
promote toxin expression from the lysogenized phage that
typically carries Stx genes. Additionally, antimotility agents
are not recommended as they can promote the sustained
presence, and consequent toxin expression, of EHEC in
the gastrointestinal tract. In instances where HUS develops,
supportive care is provided. A variety of treatment and
prevention strategies to protect against E. coli O157:H7
are currently in development; these include toxin receptor
analogs, passive antibody therapy, and vaccines to protect
humans against the systemic eﬀects of the toxin. Since an E.
coliO157:H7vaccinehasnotbeendevelopedandlicensedfor
immunization of humans (two vaccines are currently in use
in cattle [16–19]), the most promising prevention strategies
for E. coli O157:H7 focus on minimizing exposure to this
pathogen (Figure 2).
2.PathogenesisofE. coli O157:H7
E. coli O157:H7 is well adapted to cause disease in humans.
The organism has a number of virulence factors that con-
tribute to its pathogenicity, and Shiga toxin (Stx) is certainly
among them. Indeed, Stx is considered to be responsible
f o rt h es e v e r ec o m p l i c a t i o n so fE. coli O157:H7 infection,
including HUS [1, 2]. In addition to Shiga toxin, E. coli
O157:H7 expresses several other important virulence factors
that include intimin, translocated intimin receptor (or Tir),
a type three secretion system (TTSS), and enterohemolysin
(located onthe pO157plasmid) (see Figure 3). The genes for
many of these factors are located on a 44kb pathogenicity
island known as the locus of enterocyte eﬀacement, or the
LEE locus.
The Stx family of AB5 toxins (composed of a single A
oractive subunitnoncovalentlyassociated with a pentameric
ring of B or binding subunits) contains two subgroups, Stx1
and Stx2. In addition to these two Shiga toxin serotypes,
variants of each have been described: Stx1c, Stx1d, Stx2c,
Stx2d,Stx2d-activatable, Stx2e, and Stx2f(reviewed in [20]).
W h i l eS t x 1a n dS t x 2h a v et h es a m eo v e r a l ls t r u c t u r e[ 21],
these toxins are antigenically distinct such that antibody
against Stx1 will not neutralize Stx2, and vice versa [22].
Stx1 and Stx2 also have the same mode of action; however,
they diﬀer in speciﬁc activities both in vitro and in mice.
The 50% cytotoxic dose (CD50) of Stx1 for Vero cells is
lower than that for Stx2 [23], while the 50% lethal dose
(LD50) ofpuriﬁed Stx1forsystemically inoculated adult CD-
1miceis∼125ngcomparedto ∼1ngforStx2[24].Moreover
diﬀerences in toxicity are also evident when human renal
endothelial cells are treated with puriﬁed Stx1 or Stx2; Stx2
is about 1,000-fold more toxic [25]. Finally, epidemiological
data suggest a diﬀerence in Stx1 and Stx2 toxicity in people;
Stx2-producing E. coli O157:H7 strains are more frequently
associated with HUS than are strains that produce Stx1
[26–28].
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Figure 3: E. coli O157:H7 virulence factor expression and inter-
action with host cells. E. coli O157:H7 possesses a large plasmid
(pO157), carries the LEE PAI (and thus is intimin positive), and
expresses Shiga toxins. The LEE locus encodes a TTSS and TTSS
eﬀector proteins. One of the TSSS proteins, E. coli Secreted Protein
(Esp) A, forms a ﬁlament that serves to translocate TTSS eﬀector
proteins from the bacterium into the host cell by way of a pore
created by EspB and EspD. One of these eﬀectors, Tir, serves as the
receptor for the major adhesin, intimin, and thus allows adherence
of the bacterium to the host cell.
The B subunit of Stxs forms a homopentameric ring
structure as it binds the cellular toxin receptor, globotriao-
sylceramide (also known as Gb3 or CD77),a Pk blood group
antigen found on a variety of cells [29, 30]. The A1 fragment
of the A subunit is translocated into the host cell cytoplasm
[31], where it acts as an N-glycosidase to remove a single
adenosine residue from the 28S ribosomal RNA of the 60S
ribosome [32, 33]. Alteration of the 28S rRNA prevents
binding of elongation factor to the ribosome so as to inhibit
protein synthesis [34]. Stx-mediated inhibition of cellular
protein synthesis generally results in death of the intoxicated
cell by apoptosis.
Plasmid pO157 is a 93kb plasmid (∼60MDa) found
in most E. coli O157:H7 isolates as well as other EHEC
strains [35, 36]. The plasmid encodes an enterohemolysin,
an adhesin known as ToxB, and a type two secretion system
[37–39]. While the plasmid is thought to be important for
virulence (studies have correlated pO157 with hemolytic
activity [39] and intestinal adherence [40]), its exact role in
pathogenesis remains unclear (reviewed in [35]).4 Journal of Biomedicine and Biotechnology
The locus of enterocyte eﬀacement, or LEE, is a chro-
mosomally encoded pathogenicity island (PAI) that encodes
the pathogenic determinants intimin (an adhesin), a type
three secretion system (TTSS), and TTSS eﬀector proteins.
The TTSS of E. coli O157:H7 is a contact-dependent system
for transport of bacterial proteins, or eﬀe c t o r s ,i n t oh o s t
cells (such as intimin and Tir). Intimin is a 97kDa outer
membrane protein that facilitates intimate adherence of E.
coli O157:H7 to the epithelial surface [41]. Although STEC
strains that lack intimin can cause human disease [42, 43],
E. coli O157:H7 appears to require intimin to establish
colonization [44–50]. Several investigators have speculated
that E. coli O157:H7 colonization initially proceeds via
the interaction of the outer membrane protein intimin
with cell-surface-expressed factors such as β1 integrins [51]
and nucleolin [52, 53], before binding to the translocated
intimin receptor. E. coli O157:H7 is unique among bacterial
pathogens (with the exception of other LEE-encoding bacte-
ria) in that it encodes its own receptor, Tir, which is injected
into target host cells by way of the TTSS.
2.1. Models of Pathogenesis. Knowledge of the pathogenesis
of E. coli O157:H7-mediated disease in humans is quite
limited. The use of human subjects to investigate the steps
required for E. coli O157:H7 to evoke intestinal pathology
is considered unethical because of the possibility that a
volunteercoulddevelopHUS.Thus,numerousinvitroassays
and animal models have been developed in an attempt to
mimic various aspects of E. coli O157:H7 disease in humans.
In vitro systems such as cell monolayers, transwells,
organoids, and in vitro organ culture (referred to as IVOC)
as well as ex vivo cultures of biopsies are useful for the study
of several aspects of E. coli O157:H7 pathogenesis, such as
adherence of the microbe to eukaryotic cells and the impact
of Stx on those cells. In addition, the type of cells used often
depends on the speciﬁc aspect of infection and/or patho-
genesis under investigation. For example, epithelial cells
(derived from a variety of diﬀerent sources) are commonly
used to evaluate E. coli O157:H7 adherence mechanisms [47,
54], while endothelial cells (human umbilical vein endothe-
lial cells (HUVECs) or human glomerular microvascular
endothelial cells (GMVECs)) are often used to examine
the eﬀect of Stx on vascular cell integrity and cytokine
response [55]. In an attempt to model not only adherence
but also the early steps in E. coli O157:H7 pathogenesis,
polarized monolayers were generated with transwell systems.
A key feature of the transwell approach is that it allows for
the development of polarized cell monolayers that express
featuresmore characteristic ofdiﬀerentiatedcells,such asthe
formation of tight junctions and the expression of unique
cellular factors [56]. Thus, researchers have explored the
mechanisms of both E. coli O157:H7 binding to and Stx
transit across the epithelium [57, 58]. In this manner, Stx1
and Stx2 have been shown to translocate, at varying rates,
across CaCo-2A, T84, and HCT-8 cells, all of which are of
intestinal origin [59]. Another tissue culture model used
to explore E. coli O157:H7 adherence and subsequent host
cell damage is the organoid system in which cells grown
on a scaﬀold under microgravity conditions form pieces of
tissue-like material [60–62].Whenanorganoid derivedfrom
HCT-8 intestinal epithelial cells was infected with E. coli
O157:H7, attaching and eﬀacing (A/E) lesion formation and
slight tissue damage were evident; the tissue damage was
attributed to the Stx2 produced by the bacteria [63]. Finally,
in vivo grown organ cultures of intestinal samples have
been used to study adherence of E. coli O157:H7 to gut
mucosal cells and subsequent damage to the intestinal cells
[64–68].
Many animal models have been developed to facilitate
study of EHEC pathogenesis in vivo.In general, these models
exist in two varieties: those solely focused on the eﬀects
of Stx (in the absence of bacteria) and those that explore
E. coli O157:H7 infection. Models that evaluate toxicity
rely on injection of Stx (with or without LPS) and often
measure mortality as the endpoint of the investigation.
Such in vivo assays have been used to explore diﬀerences
in relative toxicity among Stx toxin types [69], to assess
the protective capacity of some factor [70–72], or to model
the pathogenesis of HUS [73]. While each applicable model
can be used to study one or more components of the steps
in the pathogenesis of E. coli O157:H7- or other STEC-
mediated disease (from initial colonization to mortality), no
one animal model system that mimics the full spectrum of
STEC-evokedillness in humans (to include the development
of HC and HUS) has been described to date (reviewed in
[74]).
Small animals that have served as models for EHEC
infection and disease include mice [75–80], rats [81], and
rabbits [82]. Larger animals that have been so used, albeit
less frequently, include chickens [83, 84], pigs [85], cows
[86], dogs [87], baboons [88], and macaques [89]. The
presence of characteristic A/E lesions in the gastrointestinal
tract of E. coli O157:H7-infected animals has been reported
in gnotobiotic piglets, infant rabbits, calves, chickens, and
macaques (reviewed in [90, 91]). Additionally, naturally
occurring HUS-like diseases have been described in grey-
hounds (known as idiopathic cutaneous and renal glomeru-
lar vasculopathy of greyhounds (CRVGs) or “Alabama rot”
[87, 92]) and rabbits [93].
3.Mouse Modelsof Infection
While large animal models, such as the gnotobiotic piglet,
exhibit anumber offeaturesofE.coliO157:H7pathogenesis,
their breeding and maintenance require considerable veteri-
nary skill, space, and ﬁnancial support. Thus, small animal
model systems are preferable for general use. Mouse models
in particular oﬀer a number of beneﬁts that include the
following: low relative costs for purchase and maintenance,
ease of care and handling, ready availability of numerous
immunological reagents, variations in genetic backgrounds
among inbred mouse strains as well as access to transgenic
and recombinant inbred animals, and, very importantly,
the feasibility of using suﬃcient numbers of animals in a
single study toperform meaningful statistical analyses on the
resultant data.Popularmouse models ofE.coliO157:H7oral
infection includeaxenicmice(noindigenousintestinal ﬂora)Journal of Biomedicine and Biotechnology 5
Table 1: Commonly used mouse models of STEC colonizationand/or disease.
Model Inoculum (CFU) Inoculation
Method Features Histopathology Source
Str-treated 1010 Feeding Colonization,morbidity, mortality
with 933cu-rev
Kidney [79]
Str-treated
(O91:H21) LD50 < 10 Feeding Colonization,morbidity, mortality Kidney [94]
MMC & str
(O157:H-) >109 (M)a IG Colonization,morbidity, mortality Kidney, brain [95]
Conventional 107,1 0 8 IG Morbidity, mortality Kidney, intestines [76]
Germfree 2 × 102 (C)a,
2 × 109 (D, M)a IG Colonization,morbidity, mortality Kidney, intestines, brain [96]
PCM 2 × 105–2 × 107 IG Colonization,morbidity, mortality Kidney, intestines, brain [77]
Conventional ∼2 × 1010 IG Colonization [97]
Germfree 5 × 107 IG Colonization,morbidity, Mortality
with hypertoxigenic strain
Kidney, intestines, brain [98]
Conventional 1011/kg IG Colonization [99]
MMC & str 5 × 103 IG Colonization,morbidity, mortality Kidney, other [78]
Germfree 102–106 IG Colonization,morbidity, mortality Kidney [75]
Conventional
(weaned) 6 × 109/kg IG Morbidity and mortality Kidney, intestines [100]
aC :c o l o n i z a t i o n ,D :d i s e a s e ,M :m o r t a l i t y .
orstreptomycin-treated mice(reducednormalﬂora)because
these animals have proven amenable to EHEC colonization.
A summary of the mouse models that have been used for E.
coli O157:H7 oral infection studies is presented in Table 1.
3.1. Development of the Streptomycin-Treated Mouse Model
for E. coli O157:H7 Infection. The ﬁrst mouse system
described for study of the pathogenesis of E. coli O157:H7
was the streptomycin-treated murine model developed by
Wadolkowski et al. [79]. This E. coli O157:H7 mouse model
incorporates streptomycin (str) treatment of animals via
their drinking water as a means of reducing the animals’
normal intestinal facultative ﬂora so as to decrease bacterial
competition for the infecting EHEC strain. This methodol-
ogy was based on the work of Myhal et al. as described in
1982 [101]. The goal of the original study by Myhal and
colleagues was to assess the relative colonizing capacities of
diﬀerent E. coli isolates. Prior to the report by Myhal et al.,
E. coli and several other bacteria (to include Salmonella and
Vibrio) were shown to have the capacity to colonize mice
if the animals had been antibiotic-treated or were axenic
[102, 103]. However, Myhal et al. demonstrated that even a
laboratory-adapted E. coli K12 given orally as a single strain
challenge was capable of colonizing str-treated mice to levels
equivalent to those observed for human fecal E. coli isolates.
Thus, as the authors suggested, str-treated mice are best used
to evaluate the relative colonization capacity of an E. coli
strain if given with another isolate in a competitive infection
study [101].
Myhal et al. used 5-6-week-old, male CD-1 (outbred
m i c e ,a l s ok n o w na sI C R )m i c e[ 101]. Myhal et al. demon-
strated that addition of 5g/L of streptomycin sulfate to the
animals’ drinking water, for as little as one day, reduced the
number of facultative anaerobes shed (from 108 CFU/g feces
prior to streptomycin treatment down to <102 CFU/g feces)
buthadlittleornoeﬀectonthenumberofobligateanaerobic
bacteria present within the gastrointestinal tract (109 CFU
shed/g feces). The authors selected streptomycin as the
antibiotic treatment of choice because they reasoned that a
mutationthatrenderedthebacteriaresistant tostreptomycin
(a presumed alteration to the ribosomes) should have little
eﬀect on the bacterial surface and thereby on colonization.
In their report, str-treated mice deprived of food/water
were infected with 1010 CFU of str-resistant E. coli in a
solution of 20% sucrose. Colony counts of feces collected
daily indicated that high levels of colonization were achieved
by all of the challenge strains when given alone (∼108 CFU/g
feces), whereas in cofeeding or competition experiments
varying colonizing capacities of the strains were observed.
Furthermore, the authors found that human fecal isolates
heavily colonized both the cecum and the large intestines.
They concluded that the large intestines, which had slightly
more adherent bacteria than were observed in the cecum,
w e r et h em a i ns i t eo fE. coli colonization in their str-treated
model [101]. This primary colonization site was consistent
with what was previously reported for E. coli colonization in
t h eu n t r e a t e dm o u s em o d e l[ 104].
Wadolkowski et al. followed a very similar methodology
to that described by Myhal et al. for their E. coli O157:H7
infection studies in str-treated mice [79, 101]. Male CD-1
mice were provided 5g/Lstreptomycin sulfate in theirdrink-
ing water to decrease the normal ﬂora prior to an overnight
fast and inoculation with 1010 CFU of the strain/s of interest
in 20% sucrose (w/v). Food was returned after infection
and animals were housed individually. Colonization levels
of the infecting E. coli O157:H7 strain were determined6 Journal of Biomedicine and Biotechnology
by enumeration of str-resistant E. coli O157:H7 in shed
feces.
Wadolkowski et al. tested three E. coli O157:H7 strains
(n = 3 per strain; experiments done in triplicate (at
least)) in their initial experiments: WT strain (933), a
pO157-cured mutant (933cu), and an additional pO157-
cured mutant recovered from co-infection studies (933cu-
rev) [79]. Strains 933 and 933cu colonized to similar levels
(107 CFU/g feces for 25 days) in single infection experiments
with no observed disease manifestation. When co-infections
were conducted, 933 outcompeted 933cu in 2/3 of the mice.
In the remaining mouse, after a decline in the load of 933cu,
there was a steady increase in levels of 933cu compared
to 933. An isolate of 933cu recovered from the co-infected
mouse was labeled 933cu-rev (“rev” meaning “revertant”
to wild-type or virulent colonization levels). Although no
signs of illness were apparent in the co-infected mouse
with the high levels of 933-cu rev, disease manifestations
were evident in mice subsequently infected with 933-cu-
rev alone. The 933cu-rev-infected mice shed loose stools,
were anorexic and lethargic, and died within a few days
of disease presentation. Extensive necropsies (included the
liver, brain, heart, stomach, small intestine, cecum, large
intestines, spleen, and kidneys) of singly infected animals
revealed that only the kidneys from animals infected with
strain 933cu-rev demonstrated pathology of any kind.
Histopathologic analysis of kidneys from 933cu-rev-infected
animals indicated widespread bilateral acute renal cortical
tubular necrosis despite apparently normal glomeruli with
no evidence of ﬁbrin deposits, elastic ﬁbers, or bacteria. The
authors concluded that this pathology was more indicative
of insult from a toxin rather than a result of dehydration that
might be expected in an anorexic animal with loose stools
[79].
In this same study, Wadolkowski et al. recovered strains
933, 933cu, and 933cu-rev from epithelial cells of the
small intestine, cecum, and large bowel. However, 933cu-
rev demonstrated an increased capacity to colonize the
small intestines and the mid and distal sections of the
large intestines compared to the other two strains. This
ﬁnding was consistent with the increased capacity of strain
933cu-rev to multiply within mucus obtained from the
diﬀerent intestinal segments (note: Wadolkowski et al. had
previously shown that multiplication in cecal mucus was
required for a human fecal isolate of E. coli to colonize
the large intestine [105]). Wadolkowski et al. went on to
speculate that the increased virulence of 933cu-rev may
have been attributable in part to its broader range of
colonization locales and, more speciﬁcally to the increased
capacity of the distal small intestines (versus the cecum
or large intestines) to absorb Stxs produced at that site
[79]. Furthermore, the link between site of colonization
and extent of disease was also suggested by Tzipori et
al. in relation to EPEC colonization [106]. Strains that
caused more severe disease colonized the proximal small
intestines of piglets, whereas strains that caused milder
pathogenesis tended to colonize distal regions of the
small intestines as well as distal portions of the large
intestines.
3.2. Extension of the Streptomycin-Treated Mouse Model for
STEC Infection. The utility of the str-treated E. coli O157:H7
colonization model was extended from the original report
of E. coli O157:H7 infection and colonization to include the
evaluation of non-O157 STEC strains [94]. Moreover, in
1994 Fujii et al. used the str-treated model to demonstrate
the developmentofneurological manifestations ofdisease by
incorporation of mitomycin C (MMC) into the treatment
regimen [95]. MMC treatment results in induction of phage
expression by the bacterium, which concurrently leads to
increases in toxin production. Agents that induce toxin
expression, to include MMC or ciproﬂoxacin treatment, are
frequently used in mouse models of STEC infection [78,
95, 107, 108]. Alterations to the str-treated model include a
reductionintheamountofbacteriafed[78,109];anincrease
in the time of streptomycin treatment prior to infection
[110, 111]; the application of intragastric inoculation of the
organism [112] ;ﬁ n a l l y ,c h a n g e si nt h es e x ,a g e ,o rs t r a i no f
mouse used [110, 112–115].
3.3. Protein-Calorie Malnutrition Mouse Model. While the
str-treated mouse model has proven particularly useful for
reproducibly attaining high levels of STEC colonization,
this animal system has limitations. For example, very high
inocula of E. coli O157:H7 are required to cause morbidity
or mortality in a portion of str-treated animals, even though
lowtomoderatedosesofSTECstrainB2F1(E.coliO91:H21)
have been used to achieve colonization of str-treated mice
and induce disease [94]. In an eﬀort to reduce the inoculum
of E. coli O157:H7 required to evoke disease in mice and to
bring the mouse inoculum closer to the predicted infectious
dose for humans (thought to be around 50 organisms
[116]), other mouse model systems have been developed.
One such system described by Kurioka et al. was based
on the observation that some children who contract STEC
infections subsisted on an unbalanced diet prior to infection
[77]. Therefore, the authors theorized that protein calorie
malnourished (PCM) mice would be more readily infected
by low doses of E. coli O157:H7 than would conventional
mice. The authors’ hypothesis proved correct in that the
minimal infectious dose of E. coli O157:H7 in PCM mice
was over 3 logs lower than that of control mice. The authors
reported pathological changes in the intestinal tract of PCM
mice infected with E. coli O157:H7 (underdevelopment
of the intestinal epithelium in response to PCM, likely
resulting in the animals’ predisposition to E. coli O157:H7
colonization) and a slight increase in TNF-α in the blood
of PCM mice compared to controls. However, they did not
observe signiﬁcant renal pathology (as was seen by Isogai
et al. [117]) but did note minimal degeneration of renal
tubules and weak staining of the cortical tubular epithelium
for Stx [77]. Kurioka et al. also postulated that retardation of
intestinal development by PCM might facilitate Stx and LPS
transit across the intestinal barrier. That Stx likely did cross
the mucosal barrier more readily in PCM-infected animals
wasstronglysuggestedbytheCNSﬁndings inthePCMmice;
cerebral hemorrhage was evident and toxin was detected
in the hippocampus. Thus, this report conﬁrmed that StxJournal of Biomedicine and Biotechnology 7
can aﬀect the CNS of mice, and can cause death of the
infected PCM mice within 10 days. These CNS ﬁndings in
E. coli O157:H7-infected PCM mice are consistent with the
observation noted by Kurioka et al. [77] that up to 30% of
STEC-infected children display neurological manifestations
of disease [118].
3.4. Germ-Free Mouse Models. In an attempt to extend the
renalpathologyevidentinstr-treated, STEC-infectedmiceto
include evidence of glomerular lesions, Isogai et al. infected
germ-free mice with E. coli O157:H7 [117]. Although these
animals became colonized with E. coli O157:H7 following
a low-dose challenge, the animals did not display signs of
disease. High inocula (comparable to those reported for the
str-treated model) were necessary to cause pathology (colon,
kidneys, and brain), disease (lethargy, paralysis, anorexia,
dehydration), and death within 7 days. However, when these
mice were treated with TNF-α a n dt h e ni n f e c t e dw i t ha
low dose of E. coli O157:H7, systemic disease, neurological
manifestations, and glomerular lesions were observed [117].
Since the initial report by Isogai et al., other groups have
used germ-free animals to evaluate E. coli O157:H7 patho-
genesis. Sawamura et al. explored the eﬀects of antibiotic
treatment on E. coliO157:H7 infection in a germ-free mouse
model they developed [119] and later used to investigate
the role of bacterial internalization by epithelial cells in
STECpathogenesis[120].Isogaiandcolleaguessubsequently
u s e dg e r m - f r e em i c et oe x p l o r et h ee ﬀects of antibiotic
and green tea extract treatment on E. coli O157:H7 disease
[96, 121–123]. Taguchi et al. developed a variation of the
germ-free mouse model in which inoculation with a hyper-
toxigenic strain of E. coli O157:H7 caused 100% mortality
among infected animals [98]. Takahashi et al. went on to
use this latter model to investigate the eﬀect of probiotics
on E. coli O157:H7 [124]. In 2007, Jeon et al. used a germ-
free mouse model to assess the virulence of a mutant strain
of E. coli O157:H7 [125]. Furthermore, Eaton and colleagues
exploited germ-free Swiss Webster mice to explore the roles
of diﬀerent E. coli O157:H7 strains and Stx types, as well as
host factors such as age and gender of the mouse [75]. Eaton
et al. reported that gut-adherent E. coli O157:H7 organisms
were seen in the ileum and cecum but not the colon. The
absence of detectable mucosally-adherent E. coli O157:H7 in
the colon of germ-free mice is in contrast to the observations
of Wadolkowski et al. in the str-treated model [79].
3.5. Conventional Mouse Models. While str-treated or axenic
animals are useful as models for assessment of disease
outcome, they rely on the absence of colonization resistance.
The term “colonization resistance” was originally coined by
van der Waaij in 1971 to explain a phenomenon whereby
“a complex intestinal microﬂora provides protection against
colonizationbymanypathogenicinfectiousagents”[107].As
a result of the partial or complete absence of a competing
microbiota in antibiotic-treated or axenic animals, the inoc-
ulated microorganism has a colonization advantage. Thus,
studies that apply these models are of limited utility for the
assessment of the capacity of an STEC strain to colonize in
the face of the physiologically more relevant situation where
normal bowel ﬂora are present.
An alternative model that did not require the alter-
ation of the indigenous ﬂora of mice was described in
1997 by Karpman and colleagues [76]. These investigators
administered high doses of E. coli O157:H7 intragastrically
to C3H/HeN and C3H/HeJ mice and reported signiﬁcant
morbidity and mortality in the infected animals. Mice in
this model developed gastrointestinal, neurological, and
systemic disease manifestations. Renal pathology included
both glomerular mesangial changes and tubular necrosis.
Focal areas of colonic necrosis were also evident. Of note,
administration of anti-Stx2 antibodies protected animals
from disease symptoms and pathology [76].
Like Karpman et al., Conlan and Perry investigated
conventional mice as a model for E. coli O157:H7 infection
[97]. In their report, Conlan and Perry considered three
strains of female mice: CD-1 (outbred), BALB/c (inbred)
and C57BL/6(inbred)toscreen potentialvaccine candidates.
Following intragastric administration of ∼1010 CFU E. coli
O157:H7 to one of the three mouse strains, fecal shedding of
the organism was monitored as a surrogate for colonization.
Although all mouse strains were colonized after infection
(generally for 1-2 weeks), no morbidity or mortality was
observed. Interestingly, only BALB/c mice seemed to be
relatively resistant to re-infection; they shed E. coli O157:H7
for a shorter duration than did other mouse strains that
had also received a second challenge with the microbe.
BALB/cmice produced more O157-speciﬁc IgA (bothserum
and fecal) in response to both primary and secondary
infection despite signiﬁcantly lower serum anti-O157 IgG
titers following secondary infection, when compared to
C57BL/6 mice. Thus, BALB/c mice can serve as models for
E. coli O157:H7 vaccine studies, despite their reported lack
of mortality and/or morbidity in the study by Conlan and
Perry [97].
The reports by Conlan and Perry and Karpman et
al. indicated that E. coli O157:H7 could colonize conven-
tional mice [76, 97]. To extend these ﬁndings, Nagano
and colleagues determined the functionality of speciﬁc
pathogen free (SPF) mice as models for E. coli O157:H7
colonization through exploration of the susceptibility of
various mouse strains to colonization after infection with
E. coli O157:H7 [99]. The mouse strains they examined
included ICR (also known as CD-1), BALB/c, C3H/HeN,
C3H/HeJ, and A/J (all female SPF mice). At one week after
infection, even with a high inoculum of E. coli O157:H7,
only the ICR animals remained colonized as a group. In
fact, the majority of ICR mice stayed colonized and shed
E. coli O157:H7 in their feces for the duration of the study
(28 days). Moreover, E. coli O157:H7 were detected in
both the cecum and the colon later in infection. However,
Nagano et al. concluded that the cecum was the primary
site of colonization because only at that location were E.
coli O157:H7 colonies observed adherent to epithelial cell
surfaces. In spite of this persistent colonization of ICR
mice by E. coli O157:H7, no morbidity or mortality was
observed after E. coli O157:H7 infection of these animals
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Recently, Brando et al. used weaned BALB/c mice to
investigate E. coliO157:H7pathogenesis [100]. Weaned mice
were selected over adult mice in an attempt to render the
animals more susceptible to E. coli O157:H7 infection; age
has been described tobe an important factor in susceptibility
of animals to EHEC disease [75]. In their model, Brando
et al. showed that only mice <21 days of age demonstrated
systemic manifestations of disease, which included mor-
tality within 96 hours and increased plasma urea levels
[100]. Occult blood was observed in the stools of mice
that succumbed to infection. Histologic analysis revealed
tubular necrosis (consistent with other STEC models) and
glomerular alterations. Only a portion of infected mice
had detectable bacteria by 72 hours after infection, and
all survivors cleared the infection by day 7. Furthermore,
only transient colonization of the small and large intestine
(the cecum was not analyzed) was observed. However,
histological analysis revealed damage to and inﬂammatory
inﬁltrates in the intestinal epithelium. The incompletely
developed intestinal epithelium in weanling mice likely
contributedtothepathologicfeaturesintheintestineandthe
systemic absorption of toxin, as was seen in PCM-infected
mice [77, 100].
3.6. Intact Commensal Flora Model. Other studies that used
conventional mice to study STEC pathogenesis can be found
in the literature, although they are less thoroughly described
[111, 126–129]. However, a common feature among many
of these conventional mouse model investigations of E. coli
O157:H7 infection was that they either assessed colonization
or monitored the development of disease. For example,
in the studies by Nagano et al. and Conlan and Perry,
colonization was followed but morbidity of infected mice
was not observed [97, 99]. Conversely, in the study by
Karpman and colleagues, morbidity and mortality were
observed but colonization was not monitored [76]. Thus,
until our report of a new conventional BALB/c mouse
model of E. coli O157:H7 infection [80], no adult mouse
studies with conventional animals that explored in detail
both colonization and disease after E. coli O157:H7 oral
infection had been reported.
We described the use of conventional BALB/c mice to
model E. coli O157:H7 oral infection [80]. Female animals
with an intact commensal ﬂora (ICF) were inoculated
with high doses (109 CFU or greater) of E. coli O157:H7
strain 86-24. Thus, E. coli O157:H7 introduced orally
by either pipette feeding or intragastric administration
(gavage) were forced to compete with commensal ﬂora
to become established within the gastrointestinal tract.
The use of an ICF animal model for studies of E. coli
O157:H7 infection and pathogenesis has the advantage of
reﬂecting a complex microbiological environment in the
gut such as that typically found in an individual who
ingests E. coli O157:H7 in contaminated food or water or
through person-to-person contact. Upon infection, mice
were colonized with E. coli O157:H7 for the seven day
course of the experiments; however, high doses of E. coli
O157:H7 were required to achieve consistent, persistent
colonization in the face of the ICF of the mouse. The
primary site of E. coli O157:H7 colonization was demon-
strated to be in the cecum of these animals. We surmised
that the bacteria were shed into the cecal content where
they transiently colonized or directly passed through the
large intestine in the luminal contents prior to becoming
encased in fecal pellets that were subsequently expelled
[80].
The ICF model of E. coli O157:H7 infection is unique
in that we were able to monitor both colonization and
disease, which included ruﬄed fur, lethargy, weight loss,
and, on average, ∼30% mortality [80]. In addition, ICF
mice infected with E. coli O157:H7 displayed evidence of
renal tubular damage with increased blood urea nitrogen
(BUN) and slightly increased levels of creatinine, both of
which canindicate renal impairment. These blood chemistry
ﬁndings are seen in patients with HUS that sometimes
follows E. coli O157:H7 infection. Therefore, through these
data and others, we inferred that Stx2 produced by E.
coli O157:H7 at the site of infection within the gas-
trointestinal tract could enter the bloodstream and harm
the kidneys of the mice in a manner analogous to that
presumed tooccurinsome E.coliO157:H7-infectedhumans
[80].
3.7. Citrobacter Rodentium as a Surrogate for E. coli O157:H7.
Another mouse model system used to evaluate the virulence
mechanisms of EHEC employs the natural mouse pathogen
Citrobacter rodentium as a surrogate for E. coli O157:H7.
C. rodentium is similar to both EPEC and EHEC in that
it carries a homolog of the LEE pathogenicity island of
EPEC and EHEC and has the capacity to evoke A/E lesions.
Thus, Citrobacter has been used to study the molecular basis
for A/E lesion formation in mice because it is the only
known LEE-positive organism that is naturally pathogenic
for rodents [130]. C. rodentium causes transmissible murine
colonic hyperplasia (TMCH) [130]. While the organism
is useful for assessment of the contribution of various
genes/proteins to virulence, this model fails to recapitulate
the pathogenesis caused by EHEC as a whole because
it does not make Shiga toxin (although there was one
report of a strain of Citrobacter freundii that produces Stx2
[131]).
3.8. Alternative Models to Oral Infection. In studies of mice
infected with E. coli O157:H7, the oral route of challenge
is used most frequently. Nevertheless, alternative means
of inoculation with STEC, although infrequent, have been
described. For instance, one of the earliest published murine
models of STEC infection relied on the subcutaneous
injection of large quantities (108 CFU) of E. coli O157:H7
into SPF mice [132]. Intravenous injection of mice with
spontaneously-derived motility mutants of E. coli O157:H7
was explored as a system to assess potential diﬀerences in
virulence of the strains [133]. Most recently, Gao et al.
evaluated the protective impact of an Stx fusion protein
vaccine on intraperitoneal challenge with E. coli O157:H7
[134].Journal of Biomedicine and Biotechnology 9
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Figure 4: Model of the role of Stx2 in E. coli O157:H7 adherence
and colonization. (a) E. coli O157:H7 elaborates Shiga toxin
early during the colonization/adherence process. Stx2 exerts an
eﬀect on the host cell epithelium that leads to increased levels
of cell surface-localized nucleolin. Nucleolin acts as an initial
receptor for intimin, an interaction that allows E. coli O157:H7
to bind to the host epithelium and inject Tir and other TTSS
eﬀectors into the host cell. Intimin then engages Tir which,
coupled with the cellular eﬀects of other TTSS eﬀectors, leads
to host cell cytoskeletal rearrangement and formation of the
characteristic A/E lesion. (b) Stx2, produced by the wild-type
organism or provided to a stx2 mutant, facilitates colonization
of the gastrointestinal tract. (c) Neutralizing anti-Stx2 antibody
present prior to and during E. coli O157:H7 infection results in
reduced levelsofE.coliO157:H7colonizationofthegastrointestinal
tract.
4.Mouse Modelsof Intoxication
HC and HUS, which are the most severe manifestations
of disease observed after infection with E. coli O157:H7 in
particular but with other STEC isolates as well, have been
attributed to the production of Stx by the organisms. As
such, mouse models are often used to explore the eﬀects of
Shiga toxin intoxication on an animal. While this can be
achieved by inoculation with toxigenic strains [135–138],
toxin is more commonly administered to mice by means
of parenteral injection [24, 69, 135, 139–142]. Injection of
puriﬁed Stx1 or Stx2 alone causes paralysis, damage to renal
cortical tubule epithelial cells, and ultimately kills mice [69].
The LD50 for Stx1 is ∼125ng and for Stx2 is ∼1ng [24];
these LD50 data conﬂict with in vitro analyses of Stx that
show that the CD50 of Stx1for Vero cells is lower than that of
Stx2 [23]. However, the mouse LD50s support data that show
that puriﬁed Stx2 is about 1,000-fold more toxic to human
renalendothelialcells[25]aswellasepidemiologicalﬁndings
that suggest a diﬀerence in Stx1 and Stx2 toxicity for people;
Stx2-producing E. coli O157:H7 strains are more frequently
associated with HUS than are strains that produce Stx1 [26–
28]. Mice fed Stx2-producing DH5α experienced mortality
and exhibitedrenal lesions similar tothose observedinSTEC
(E. coli O91:H21)-infected mice [135].
4.1. Administration of Stx and Endotoxin. Because injection
ofStxalone initially failed to recapitulateall featuresofHUS,
a mouse model that mimics the course of human E. coli
O157:H7 disease was developed. In this model, mice were
injected with a combination of Stx and LPS [139–141, 143,
144]. Systemic exposure to both virulence factors caused
characteristic features of HUS that included neutrophilia,
thrombocytopenia, red cell hemolysis, and increased BUN
and creatinine levels [139]. In addition, evidence of ﬁbrin
deposition and red blood cell inﬁltration were observed in
the glomeruli, capillaries, and intertubular spaces [139]. The
renal damage was caused by Stx-induced apoptosis of the
Gb3-expressing renal cortical and medullary tubular cells,
which led to loss of function in the renal collecting ducts
and subsequent dehydration [140] .T h er o l eo fL P Si nt h e
mouse model of HUS, however, is controversial. Palermo
et al. determined that mortality caused by Stx and LPS
was dependent on the timing of the LPS administration
relative to Stx intoxication [145]. In contrast, Suzuki et al.
observednosynergistic eﬀectofcoadministration ofLPSand
Stx based on analysis of cytokine induction and mortality
[146]. Recent studies demonstrated that repeated exposure
to sublethal doses of Stx2 in the absence of LPS resulted in
the developmentoffeaturesof HUS[73].Extendedexposure
to Stx would be expected following infection with E. coli
O157:H7 or another STEC.
4.2. Feeding of Stx. It has been postulated that toxin pro-
duced by E. coli O157:H7 and liberated into consumables
m a yr e s u l ti ni n t o x i c a t i o ni nt h ea b s e n c eo fi n f e c t i o n
[147]. To test this hypothesis in a mouse model, toxin was
delivered to mice orally in an attempt to cause systemic10 Journal of Biomedicine and Biotechnology
intoxication. Our lab found that mice fed large amounts of
Stx2 succumbed to the eﬀects of toxin (unpublished data).
Furthermore, Rasooly and colleagues showed that mice fed
Stx also died within a few days of oral intoxication [148].
In their study, toxin-mediated damage to distal organs was
observed, which indicated that Stx was able to migrate out of
the digestive tract in the absence of E. coli O157:H7 [148].
5.ApplicationsofMouse Models
5.1. The Role of Stx. In 2006, Robinson et al. demonstrated
thatStx2facilitatedadherenceofE.coliO157:H7toepithelial
cells in vitro and colonization of the intestine in vivo [149].
They showed that an isogenic E. coli O157:H7 stx2 mutant
adhered to HEp-2 cells to a lesser extent than did the wild-
type E. coli O157:H7 strain; furthermore, this adherence
deﬁciency could be overcome by treatment of the HEp-2
cells with puriﬁed Stx2. In single infections of conventional
mice, the Stx2-producing wild-type E. coli O157:H7 strain
colonized the mouse intestine at signiﬁcantly higher levels
than did its isogenic stx2 mutant. However, in a co-infection,
the E. coli O157:H7 wild-type and stx2 mutant strains
colonized mice similarly. These data led Robinson et al. to
concludethatStx2producedbythewild-typecomplemented
the stx2 defect in the mutant in vivo [149]. Stx was also
shown to facilitate colonization of C57BL/6 mice with E. coli
O157:H7 [150]. Calderon-Toledo et al. reported higher E.
coli O157:H7 counts in the feces of str-treated mice infected
with a Stx2-producing strain when compared to a Stx2-
nonproducing strain [150].
More recently, we conﬁrmed the capacity of Stx2 to
promote E. coli O157:H7 colonization in the ICF mouse
model [151]. In our study, we exogenously supplied Stx2 to
anstx2 mutantE.coliO157:H7.This additionofStx2in trans
to the stx2 mutant restored the capacity of the mutant to
colonize the intestines of mice with an ICF. Furthermore, we
discovered that anti-Stx2 neutralizing antibodies adminis-
tered prior to infection signiﬁcantly decreased the likelihood
that a mouse would become highly colonized with E. coli
O157:H7. We also conﬁrmed that these Stx2-neutralizing
antibodies could protect E. coli O157:H7-infected mice
against manifestations of Stx2-mediated disease such as
weightlossanddeath.Moreover,micerepeatedlyimmunized
with a Stx2 toxoid developed a Stx2-neutralizing fecal
antibody response; when challenged with E. coli O157:H7,
immunized mice shed fewer organisms in their feces for
a shorter duration than did sham-vaccinated control mice
[151].
5.2. The Role of Gb3. For Stx to intoxicate a host, either
directly via injection or by infection with STEC, the toxin
must gain entry into host cells by binding to the Stx
receptor Gb3. Thus, for an animal model of Stx intoxication
to be relevant, surface-expressed Gb3 must be present in
the host. In addition, the degree of receptor expression
by particular cells dictates the focus of toxin damage. In
humans, the gene that encodes the Gb3 synthase is expressed
to varying levels in the heart, kidney, spleen, liver, lung,
stomach, small intestine, and colon [152, 153]. Furthermore,
Gb3-expressing cells have been identiﬁed in the colon,
endothelium, kidney, and CNS [153–160].
In mice, Okuda and colleagues used Gb3 knockout mice
to demonstrate that the eﬀects of Stx injection are indeed
dependent on the expression of Gb3 [161]. The concept that
Gb3 may be diﬀerentially distributed in murine tissues in
comparison to human tissue was supported by the work
of Fujii et al., who reported that the Gb3 synthase gene is
expressed most highly in the kidney and lungs, with lower
expression levels in the brain, heart, gastrointestinal tract,
and spleen [162]. They and others have shown that the
actual glycolipid Gb3 is present in the kidney (tubules but
notglomeruli,despitereports oftoxin-associated glomerular
damage [73, 76, 139, 144, 161]), as well as the lung, brain,
and spleen [69, 161, 163, 164]. In summation, even though
the relative Gb3 expression levels between humans and mice
are notknown, theoveralltissuedistributionofGb3between
adult humans and mice appears to be similar.
5.3. Stx and Pathogenesis. The use of mouse models to
explore the role of Stx, arguably the most important
virulence factor of E. coli O157:H7, in colonization and
disease has served to provide a better understanding of E.
coli O157:H7 pathogenesis. A model has been postulated
whereby the bacteria enter the gastrointestinal tract and then
transit to the primary site ofcolonization (the cecumin mice
[80, 99]) where they then elaborate Stx2. Data generated
in vitro with HEp-2 cells indicate that the action of the
t o x i nc a u s e sa ni n c r e a s ei nc e l ls u r f a c e - l o c a l i z e dn u c l e o l i n
[149]. Nucleolin is a eukaryotic-binding partner for intimin
and thus a eukaryotic receptor for intimin-expressing E. coli
O157:H7 [48, 52]. Intimin from the E. coli O157:H7 and
cell-surface nucleolin interact to provide an initial point of
attachment for the bacterium. Once the organism associates
with the host cell via the intimin/nucleolin interaction,
intimin bindstoTir, thebacterially encodedintimin receptor
that is translocated by the TTSS into the host cell. The
intimin/Tir interaction, coupled with the eﬀects of other
TTSS eﬀector proteins, culminates in the formation of the
characteristic A/E lesion/pedestal (Figure 4(a)).
Stx2 production may occur during transit of the organ-
ism through the intestines. Stx2 was found in the cecum and
at other sites where E. coli O157:H7 were abundant early in
infection [80]. Furthermore, in our study, Stx2 was more
abundant in the cecal and large intestinal luminal contents
than in the corresponding tissue; these observations may
indicate that toxin is absorbed into the circulation from both
t h ec e c u ma n dt h el a r g ei n t e s t i n e[ 80]. At least a portion of
thetoxinproducedwithinthegastrointestinal tractentersthe
bloodstream because (1) renal tubular damage was evident
in infected mice, and toxin was detected in the kidney of at
leastoneinfected animal [80],and (2)parenteral inoculation
of antitoxin antibody protected mice from the systemic
manifestations of disease [151].
Given that Stx not only acts systemically but also
facilitates E. coli O157:H7 colonization [151], a therapeutic
strategy directed against toxin has potential to be quiteJournal of Biomedicine and Biotechnology 11
beneﬁcial. To this end, we demonstrated that toxin provided
exogenously to a toxin-null mutant resulted in increased
E. coli O157:H7 colonization [151]. Thus, toxin, produced
by the wild-type or provided exogenously to the mutant,
had the capacity to increase the colonization levels of
E. coli O157:H7 in mice (Figure 4(b)). Additionally, anti-
toxin antibody, either administered to animals or actively
generated following vaccination, reduced the overall levelsof
E. coli O157:H7 shed by mice and protected animals from
systemic manifestations of disease (Figure 4(c)).
6.Conclusions
As a result of the increased rate of HUS over the last
several years and the lack of therapies for treatment of HUS,
further research is necessary to deﬁne mechanisms involved
in the pathogenesis of E. coli O157:H7 and to identify
potential disease prevention strategies and therapeutics. The
application of animal model systems is vital to achieve these
goals. While no one model recapitulates all features of E.
coli O157:H7 infection, many valuable mouse models have
been developed that permit exploration of E. coli O157:H7
pathogenesis and that can help pinpoint the means by which
E. coli O157:H7 infection and/or disease can be controlled or
prevented.
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